CD28 and melanoma: Herein we collect preliminary evidence that CD28 abs of melanoma patients in fact have inhibitory effects on the CD28 receptor of Jurkat cells and lead to a titer-dependent reduced stimulation of Jukat cells in vitro. Further T-cell assays are warranted to investigate the role of CD28 serum abs on T-cells from melanoma patients.